Nyxoah S.A.

NasdaqGM NYXH

Nyxoah S.A. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD 35.33 M

Nyxoah S.A. Net Cash Used For Investing Activities is USD 35.33 M for the year ending December 31, 2023, a 136.71% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Nyxoah S.A. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -96.24 M, a -615.42% change year over year.
Nyxoah S.A. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -13.45 M, a -2.98% change year over year.
Nyxoah S.A. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -13.06 M, a -100.85% change year over year.
Nyxoah S.A. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -6.50 M, a -7,476.45% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	146
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Dental Care Medical Instruments Pharmaceuticals Pollution Treatment Telehealth

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key trends

Past 5 years